However, the major interest in HER-2/neu amplification lies in its utility as a predictive marker of responsiveness to therapy [11] primarily, the response of breast cancer patients to chemotherapy, hormonal therapy (antiestrogens) and therapeutic anti-HER-2 antibodies. Here, ERBB2 is linked to breast carcinoma.